Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.

@article{Giovannoni2011SustainedDS,
  title={Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.},
  author={Gavin Giovannoni and S. D. Noam Cook and Kottil W. Rammohan and Peter Rieckmann and Per Soelberg S\orensen and Patrick Vermersch and Anthony C. Hamlett and Vissia Viglietta and Steven J. Greenberg},
  journal={The Lancet. Neurology},
  year={2011},
  volume={10 4},
  pages={329-37}
}
BACKGROUND On the basis of various clinical and MRI measurements, the phase 3 Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY) study in patients with relapsing-remitting multiple sclerosis (RRMS) showed that short-course oral treatment with cladribine at cumulative doses of 3·5 and 5·25 mg/kg over 96 weeks was more effective than placebo. Achieving sustained freedom from disease activity is becoming a viable treatment goal in RRMS; we therefore aimed to assess the effects of… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.
56 Citations
1 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 56 extracted citations

References

Publications referenced by this paper.

Similar Papers

Loading similar papers…